Key result
The AT1R A1166C polymorphism C allele was associated with a shorter time from diagnosis to ESRD onset compared to the homozygous AA genotype (4.7 vs 12.6 years, P<0.001).
Why the study?
Are renin-angiotensin system gene polymorphisms associated with the development and rate of progression to end-stage renal disease?
Case-Control (n=1,265)
Are renin-angiotensin system gene polymorphisms associated with the development and rate of progression to end-stage renal disease?
Absolute Event Rate: 4.7% vs 12.6%
p-value: p=<0.001
The AT1R A1166C gene polymorphism is associated with a significantly faster progression to end-stage renal disease, independent of hypertension.
AT1R A1166C C allele may flag faster CKD progression; leaves open whether genotyping improves risk stratification or management.
BACKGROUND: End-stage renal disease (ESRD) is a complex phenotype resulting from underlying kidney diseases of different etiologies as well as from environmental and genetic factors. The responsible genes influencing the development and rate of progression to ESRD have yet to be defined. We examined an association of the three renin-angiotensin system (RAS) gene polymorphisms with renal disease and progression to ESRD in dialyzed patients. METHODS: Genotyping was performed in 745 ESRD patients and 520 control subjects for the angiotensin-converting enzyme (ACE) I/D, angiotensinogen (AGT) M235T and angiotensin II type 1 receptor (AT1R) A1166C gene polymorphisms using polymerase chain reaction and gel analysis. RESULTS: Allele and genotype frequencies of the ACE polymorphism did not differ significantly between ESRD patients and controls. The patient group showed an increased frequency of the T allele of the AGT polymorphism (P = 0.02) and the C allele and CC genotype of the AT1R polymorphism (P<0.01). There was an association of the AT1R gene polymorphism with the progression of renal disease to end-stage failure. The time from diagnosis to the onset of ESRD was significantly shorter in patients carrying the C allele than in subjects with the homozygous AA genotype (4.7 years vs 12.6 years, P<0.001). The observed effect was not associated with hypertension in studied subjects. CONCLUSION: The results of our study demonstrate the association between the AT1R A/C polymorphism and renal disease progression. The CC/AC genotype of this polymorphism might serve as a predictor for early ESRD and might be useful in planning therapeutic strategies for individual patients.
No takes yet. Share an insight, caveat, or question.
Buraczyńska et al. (2005) conducted a case-control in End-stage renal disease (n=1,265). AT1R A1166C and AGT M235T gene polymorphisms vs. Control subjects or homozygous AA genotype was evaluated on Time from diagnosis to the onset of ESRD (p=<0.001). The AT1R A1166C polymorphism C allele was associated with a shorter time from diagnosis to ESRD onset compared to the homozygous AA genotype (4.7 vs 12.6 years, P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: